Drug intelligence / Profile preview

TRB-071

Development stage: Preclinical
Lead developer: TRexBio

Overview

TRB-071 is an investigational large molecule biological therapeutic in early preclinical development by TRex Bio. It is part of a pipeline focused on immune modulation for the treatment of inflammatory and autoimmune diseases, as well as fibrosis. While specific details about its mechanism of action have not been disclosed publicly, it is being developed using TRex Bio’s Deep Biology platform, which aims to identify novel tissue immune-regulation targets. The drug is currently in the early stages of development and has not yet entered clinical trials[1][2][4][9].

Beyond the preview

Go deeper on TRB-071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRB-071.

Explore the full profile